Uncategorized
Alimera sees second quarter revenue increase
Alimera Sciences had an increase in consolidated net revenue of 8% to $10.4 million in the second quarter of 2017 compared with $9.6 million in the second quarter of 2016. U.S. revenue increased from $7.2 million to $8.1 million, driven by higher sales of Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg), while international revenue remained flat at $2.3 million, according to a company press release.